{
    "text_blocks": {
        "data": {
            "block_count": 1,
            "table_index": 0
        },
        "model": null,
        "timestamp": "2025-01-21_09-31-30"
    },
    "table_comments": {
        "data": "CONSOLIDATED BALANCE SHEETS\tDollars in Millions\t(UNAUDITED)\t",
        "timestamp": "2025-03-11_12-12-58"
    },
    "units": {
        "data": {
            "sum_units": 1000000,
            "sum_divider": 1.0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1000000",
                    "1": "1000000"
                },
                "decision": "1000000"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-13-02"
    },
    "post_table_text": {
        "data": "\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBRISTOL-M",
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "'\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBRISTOL-M'"
                },
                "decision": "'\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBRISTOL-M'"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-13-03"
    },
    "table_body": {
        "data": "ASSETS\tSeptember 30,\t2019\tDecember 31,\t2018\tCurrent Assets:\tCash and cash equivalents\t$\t30,489\t$\t6,911\tMarketable securities\t2,053\t1,973\tReceivables\t5,510\t5,965\tInventories\t1,192\t1,195\tPrepaid expenses and other\t947\t1,116\tTotal Current Assets\t40,191\t17,160\tProperty, plant and equipment\t4,830\t5,027\tGoodwill\t6,513\t6,538\tOther intangible assets\t1,002\t1,091\tDeferred income taxes\t1,624\t1,371\tMarketable securities\t925\t1,775\tOther assets\t2,348\t2,024\tTotal Assets\t$\t57,433\t$\t34,986\tLIABILITIES\tCurrent Liabilities:\tShort-term debt obligations\t$\t569\t$\t1,703\tAccounts payable\t1,888\t1,892\tAccrued and other current liabilities\t8,032\t7,059\tTotal Current Liabilities\t10,489\t10,654\tIncome taxes payable\t2,919\t3,043\tOther non-current liabilities\t1,881\t1,516\tLong-term debt\t24,390\t5,646\tTotal Liabilities\t39,679\t20,859\tCommitments and contingencies\tEQUITY\tBristol-Myers Squibb Company Shareholders  Equity:\tPreferred stock\t \t \tCommon stock\t221\t221\tCapital in excess of par value of stock\t2,206\t2,081\tAccumulated other comprehensive loss\t(\t1,463\t)\t(\t2,762\t)\tRetained earnings\t36,555\t34,065\tLess cost of treasury stock\t(\t19,871\t)\t(\t19,574\t)\tTotal Bristol-Myers Squibb Company Shareholders  Equity\t17,648\t14,031\tNoncontrolling interest\t106\t96\tTotal Equity\t17,754\t14,127\tTotal Liabilities and Equity\t$\t57,433\t$\t34,986",
        "timestamp": "2025-03-11_12-13-03"
    },
    "table_json_created": {
        "data": true,
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "{\"ASSETS\": {\"Current Assets\": {\"Cash and cash equivalents\": [30489, 6911], \"Marketable securities\": [2053, 1973], \"Receivables\": [5510, 5965], \"Inventories\": [1192, 1195], \"Prepaid expenses and other\": [947, 1116], \"Total Current Assets\": [40191, 17160]}, \"Property, plant and equipment\": [4830, 5027], \"Goodwill\": [6513, 6538], \"Other intangible assets\": [1002, 1091], \"Deferred income taxes\": [1624, 1371], \"Marketable securities\": [925, 1775], \"Other assets\": [2348, 2024], \"Total Assets\": [57433, 34986]}, \"LIABILITIES\": {\"Current Liabilities\": {\"Short-term debt obligations\": [569, 1703], \"Accounts payable\": [1888, 1892], \"Accrued and other current liabilities\": [8032, 7059], \"Total Current Liabilities\": [10489, 10654]}, \"Income taxes payable\": [2919, 3043], \"Other non-current liabilities\": [1881, 1516], \"Long-term debt\": [24390, 5646], \"Total Liabilities\": [39679, 20859], \"Commitments and contingencies\": null}, \"EQUITY\": {\"Bristol-Myers Squibb Company Shareholders Equity\": {\"Preferred stock\": [0, 0], \"Common stock\": [221, 221], \"Capital in excess of par value of stock\": [2206, 2081], \"Accumulated other comprehensive loss\": [-1463, -2762], \"Retained earnings\": [36555, 34065], \"Less cost of treasury stock\": [-19871, -19574], \"Total Bristol-Myers Squibb Company Shareholders Equity\": [17648, 14031]}, \"Noncontrolling interest\": [106, 96], \"Total Equity\": [17754, 14127]}, \"Total Liabilities and Equity\": [57433, 34986]}"
                },
                "decision": "{\"ASSETS\": {\"Current Assets\": {\"Cash and cash equivalents\": [30489, 6911], \"Marketable securities\": [2053, 1973], \"Receivables\": [5510, 5965], \"Inventories\": [1192, 1195], \"Prepaid expenses and other\": [947, 1116], \"Total Current Assets\": [40191, 17160]}, \"Property, plant and equipment\": [4830, 5027], \"Goodwill\": [6513, 6538], \"Other intangible assets\": [1002, 1091], \"Deferred income taxes\": [1624, 1371], \"Marketable securities\": [925, 1775], \"Other assets\": [2348, 2024], \"Total Assets\": [57433, 34986]}, \"LIABILITIES\": {\"Current Liabilities\": {\"Short-term debt obligations\": [569, 1703], \"Accounts payable\": [1888, 1892], \"Accrued and other current liabilities\": [8032, 7059], \"Total Current Liabilities\": [10489, 10654]}, \"Income taxes payable\": [2919, 3043], \"Other non-current liabilities\": [1881, 1516], \"Long-term debt\": [24390, 5646], \"Total Liabilities\": [39679, 20859], \"Commitments and contingencies\": null}, \"EQUITY\": {\"Bristol-Myers Squibb Company Shareholders Equity\": {\"Preferred stock\": [0, 0], \"Common stock\": [221, 221], \"Capital in excess of par value of stock\": [2206, 2081], \"Accumulated other comprehensive loss\": [-1463, -2762], \"Retained earnings\": [36555, 34065], \"Less cost of treasury stock\": [-19871, -19574], \"Total Bristol-Myers Squibb Company Shareholders Equity\": [17648, 14031]}, \"Noncontrolling interest\": [106, 96], \"Total Equity\": [17754, 14127]}, \"Total Liabilities and Equity\": [57433, 34986]}"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-12_11-21-01"
    },
    "problems": {
        "data": [],
        "timestamp": "2025-03-12_11-21-01"
    }
}